@American_Heart’s official account for meetings, science news, funding opportunities and membership. RTs/Follows not endorsements. Pump up your career, here.
US Veterans make up more than 5% of the US adult population. Compared with the general US population, Veterans are older, have more comorbidities, and face unique structural barriers, including high rates of rural location and less internet access. With time, the makeup of Veterans is becoming increasingly diverse in race, ethnicity, age, gender, and military exposure history.
Veterans receiving care in the Veterans Administration (VA) have higher rates of obesity, diabetes, hyperlipidemia, hypertension, and sleep disorders compared to the general population. Data from the Million Veteran Program show that fewer than 5% of Veterans achieve optimal cardiovascular health based on the American Heart Association’s Life’s Essential 8 domains, which in turn has been associated with reduced life expectancy.
✍🏼 @yuanneal @AIDALMARZOOQ @wccushman@jenmartinsleeps@Lisa_Jackson_MD
📷 Meeting the cardiovascular health promotion needs of US veterans: challenges and responses.
https://t.co/9TM4zzc6DM
AI is transforming cardiovascular care at the point of care, creating new opportunities to close the gap between scientific discovery and patient care. At #ScientificSessions26, past American Heart Association President Bob Harrington, MD, FAHA and OpenAI's Nate Gross, MD, explored how AI can help accelerate the future of medicine. 💡
@HeartBobH, @NG
As #ScientificSessions26 comes to a close, we celebrate the science, innovation and collaboration that continue to shape the future of cardiovascular and brain health.
Now, we look ahead to a historic milestone.
Join us in Boston for the 100th Scientific Sessions, Nov. 5-8, 2027.
@HeartDocSadiya@bnallamo
#ScientificSessions27
SYNCHRONIZE-CVOT results presented at #ScientificSessions26
In adults with obesity and established cardiovascular or chronic kidney disease, or increased cardiovascular risk, survodutide was non-inferior to placebo for a composite of cardiovascular death, non-fatal cardiovascular events, coronary revascularization, and heart failure events, while also improving cardiometabolic markers.
🧵/ Late breaking science results from #ScientificSessions26 will be posted to this thread at the time of presentation:
ZEUS
Lp(a) HORIZON
OCEANIC-STROKE
REDUCE
OPTIMAL-Stroke
STREAM
Yoga-CaRe HF Trial
SUPERIOR
RACE-CARS
ATTAIN-OSA
SYNCHRONIZE-CVOT
⬇️
(bookmark this post)
ATTAIN-OSA results presented at #ScientificSessions26
Among adults with moderate-to-severe OSA and overweight or obesity without diabetes, orforglipron significantly reduced apnea-hypopnea index compared with placebo at 52 weeks, both in participants using and not using positive airway pressure therapy.
SYNCHRONIZE-CVOT results presented at #ScientificSessions26
In adults with obesity and established cardiovascular or chronic kidney disease, or increased cardiovascular risk, survodutide was non-inferior to placebo for a composite of cardiovascular death, non-fatal cardiovascular events, coronary revascularization, and heart failure events, while also improving cardiometabolic markers.
ATTAIN-OSA results presented at #ScientificSessions26
Among adults with moderate-to-severe OSA and overweight or obesity without diabetes, orforglipron significantly reduced apnea-hypopnea index compared with placebo at 52 weeks, both in participants using and not using positive airway pressure therapy.
Science shared at #ScientificSessions26 is reshaping how we think about menopause and cardiovascular health. Explore educational content today.
Learn more: https://t.co/YQrtoEUvF4
Women's health is having a major moment at #ScientificSessions26. Jennifer Ashton, MD, MS, FACOG, is helping drive important discussions around menopause, women's cardiovascular health, and the latest insights shaping care for women across every stage of life.
RACE-CARS results presented at #ScientificSessions26
Compared with usual care, the multifaceted intervention did not result in a greater percentage of patients who survived to hospital discharge with a favorable neurologic outcome.
SUPERIOR results presented at #ScientificSessions26
Sacubitril/valsartan reduced the risk of documented atrial tachyarrhythmia recurrence at 12 months compared to valsartan in older patients with HTN undergoing catheter ablation for AF.